Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification Rami S. KomrokjiJohn M. Bennett OriginalPaper Pages: 9 - 15
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good? Mikkael A. SekeresAlan List OriginalPaper Pages: 16 - 19
Farnesyltransferase inhibitors in myelodysplastic syndrome E. J. Feldman OriginalPaper Pages: 20 - 24
Arsenic trioxide as a treatment for myelodysplastic syndrome Mikkael A Sekeres OriginalPaper Pages: 34 - 38
Initial chemotherapy for chronic lymphocytic leukemia: What’s the standard of care? Matt Kalaycio Clinical Trials Report Pages: 41 - 42
Advances in the treatment of chronic lymphocytic leukemia Nicole Lamanna OriginalPaper Pages: 43 - 48
First-line treatment of Hodgkin’s lymphoma Beate KlimmAndreas EngertVolker Diehl OriginalPaper Pages: 51 - 59
Nodular lymphocyte-predominant Hodgkin’s lymphoma Lucia NogovàVolker Diehlthe German Hodgkin Study Group OriginalPaper Pages: 60 - 65